Spinocerebellar ataxia type 1 (SCA1) is a polyglutamine (polyQ) repeat neurodegenerative disease in which a primary site of pathogenesis are cerebellar Purkinje cells. In addition to polyQ expansion of ataxin-1 protein (ATXN1), phosphorylation of ATXN1 at the serine 776 residue (ATXN1-pS776) plays a significant role in protein toxicity. Utilizing a biochemical approach, pharmacological agents and cell-based assays, including SCA1 patient iPSC-derived neurons, we examine the role of Protein 
Introduction
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by expansion of a polyCAG repeat within the coding region of the ataxin-1 gene (ATXN1 or SCA1) (see Kraus-Perrotta and Lagalwar [1] for review). This expansion increases the length of a polyglutamine (polyQ) tract within the Ataxin1 protein (ATXN1) with expansion length directly correlating with the severity and age of onset of SCA1 [2] . SCA1 is characterized neurologically by ataxia, dysarthria, dysphagia, and bulbar dysfunction. A key pathological finding in SCA1 is the loss of Purkinje cells (PCs) from the cerebellar cortex [3, 4] .
Experimental reduction of ATXN1 in a mouse model of SCA1 dampens cerebellar pathology and motor deficits induced by ATXN1 with an expanded polyQ tract [5] [6] [7] . In a murine model of the Purkinje cell component of SCA1, phosphorylation of ATXN1 at serine 776 (ATXN1-pS776) is crucial to disease pathogenesis and progression. Transgenic mice that express the expanded protein containing a phosphoresistant alanine at 776 (ATXN1[82Q]-S776A) develop mild, late-onset asymptomatic cerebellar cortex atrophy only when crossed to homozygosity [8] . In contrast, transgenic mice lacking the polyglutamine expansion mutation but harboring an irreversible phosphomimetic aspartic acid at 776 (ATXN1[30Q]-S776D) manifest motor deficits of disease [9] . In the cerebellum, a consequence of S776 phosphorylation is cytoplasmic stabilization of ATXN1 [10, 11] . ATXN1[30Q]-S776A transgenic mice feature a 10-fold lower ATXN1 protein/mRNA ratio than ATXN1[30Q]-S776 transgenic mice [12] .
Stability of phosphorylated ATXN1 is regulated through the interaction of phospho-S776
A C C E P T E D M A N U S C R I P T 4 with the molecular chaperone 14-3-3 [13] . Binding to 14-3-3 protects ATXN1 against dephosphorylation by cytoplasmic phosphatases [14] .
Within the nucleus, phosphorylation of ATXN1-S776 reduces binding to the spliceosomal element U2AF65 [15] and enhances binding to the splicing factor RBM17 [16] . Importantly, interaction of ATXN1-S776 with RBM17 increases with increasing length of the polyQ tract while the interaction of RBM17 with ATXN1-S776A is decreased dramatically regardless of polyQ tract length. Furthermore, the interaction of RBM17 with ATXN1[30Q]-S776D is enhanced like that seen with ATXN1[82Q]-S776 [16] .
Given the seminal role S776 phosphorylation plays in regulating ATXN1 biochemistry and function, identification of the biologically active kinase(s) in the central nervous system is of considerable importance. An initial study identified the kinase Akt in phosphorylation of ATXN1 at S776 in non-cerebellar tissue culture cells and a Drosophila retinal model of SCA1 [13] . However, co-expression of ATXN1[30Q]-S776 or ATXN1[82Q]-S776 with a dominant-negative form of Akt in mouse Purkinje cells did not diminish ATXN1-pS776 [12] . A parallel Drosophila and cell-based screen revealed the involvement of the RAS-MAPK-MSK1 pathway in regulation of ATXN1 levels via S776 phosphorylation [17] . Importantly, this study demonstrated that reductions in Msk levels dampen disease severity in vivo using two SCA1 mouse models. In addition, immunodepletion and pharmacological strategies indicate that cAMP-dependent protein kinase (PKA) may also be a biologically relevant kinase for ATXN1-S776 phosphorylation in the mammalian cerebellum [12] . Consistent with this finding is the observation that postnatal day 7 ATXN1[82Q] mouse cerebellar slices treated with A C C E P T E D M A N U S C R I P T 5 forskolin, a PKA pathway activator, displayed enhanced dendritic morphological abnormalities similar to those seen in aged ATXN1[82Q] mice [18] . Correspondingly, application of an inhibitory PKA peptide improved SCA1 Purkinje cell morphology in ATXN1[82Q] mouse cerebellar slices [19] .
In the present study, we use pharmacological and genetic approaches to further examine the biological role of PKA as a kinase for ATXN1-S776 phosphorylation and its implications in SCA1. We demonstrate that inhibition of phosphorylation at the S776 residue results in rapid degradation of Atxn1/ATXN1 protein in several mammalian neural experimental systems, including SCA1 patient iPSC-derived neuronal cells.
Moreover, reduction of the PKA catalytic subunit Cα in Pcp2-ATXN1[82Q] mice reduces ATXN1[82Q]-S776 phosphorylation, lowers Purkinje cell ATXN1 levels, and delays onset of cerebellar-dependent motor deficits. These data provide further insight into how the dynamic nature of ATXN1, regulated through S776 phosphorylation, impacts disease.
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Materials and Methods
Reagents
1 and 2 provide information on the antibodies and pharmacological compounds used in this study. Table 1 Antibodies used for western blotting (WB) and in MESO phosphorylation assay Committee approved all animal use protocols. All mice were housed and managed by
Research Animal Resources under SPF conditions in an AAALAC-approved facility. In all experiments, equal numbers of male and females were used.
In vitro kinase assay
Three gBlocks were designed to encode human Ataxin-1 [30Q] with codons optimized for expression in E.coli K-12 (IDT technologies). Gibson cloning was performed using the pET28a vector and the three gBlocks to generate a protein expression vector with a 6X-His tag and a TEV cleavage site. This construct was transformed in BL21AI One Shot E. coli and Ataxin-1 [30Q] expression was induced with 0.5 mM IPTG and 0.2% Larabinose for 4 hours at 37°C. The bacteria were lysed using sonication and 1% Triton X-100 in lysis buffer (6 M urea 20 mM BME 0.5 M NaCl 30 mM Imidazole 50 mM NaPO4 pH 7.4). The supernatant was then loaded onto a pre-packed 5 mL high performance Ni sepharose column (GE healthcare). Elution was performed using a step gradient of 330 mM imidazole in lysis buffer. Fractions with >80% purity were used in the kinase assays. EDTA, 0.1 mg/mL BSA, 1 mM dithiothreitol (DTT)) with phosphatase inhibitor (Roche) and 100 µM ATP (Invitrogen) for 1 hour at 30°C. The kinase reaction was terminated by the addition of NuPAGE LDS sample buffer and sample reducing agent (Invitorgen)
followed by boiling for 15 min. Samples were run on NuPAGE 4-12% Bis-Tris Gels (Invitrogen) and stained with InstantBlue Protein Stain (Expedeon) for 1 hour at room temperature. The bands corresponding to Ataxin-1 were extracted, subject to trypsin digestion and analyzed by the Mass Spectrometry-Proteomics Core Laboratory at Baylor
College of Medicine using LC-MS/MS on an AB SCIEX TripleTOF 5600 mass spectrometer.
IC50 Profiling
IC50 profiles of GSK690693 and staurosporine were tested against AKT1 (Upstate, cat.
no. 14-276), MSK1 (Upstate, cat. no. 14-548M), MSK2 (Upstate, 14-616), PKA (Sigma, cat. no. C8482, PRKACA) and ROCK2 (CARNA, cat. no. 01-110) by Nanosyn. Kinase assays were run in a 12-point dose response format in duplicate wells in two independent trials and fitted to sigmoidal dose-response curves. Confidence intervals of 95% and Hill coefficients were calculated. [17] were grown on 35mm culture plates, transferred to RC-30HV imaging chambers (Warner Instruments 64-0321), heated to 37 °C using a dual automatic temperature controller (Warner TC-344C), and imaged for brightfield and RFP with an Olympus IX-70 inverted light microscope equipped with fluorescent optics and an Olympus DP71 digital camera. 10 nM staurosporine or DMSO vehicle were added to the plates at time zero; images were captured every 2 minutes and processed using Adobe Photoshop.
Live cell imaging
DAOY cells stably-expressing RFP-ATXN1[82Q]-IRES-YFP
GSK690693 inhibition of ATXN1[82Q] phosphorylation (modified MESO assay)
The MESO assay in which compound GSK690693 was analyzed was modified slightly to allow use of the mouse monoclonal antibody specific for pS776 of ATXN1. MESO 96-well Small Spot Glutathione plates (MESO Scale Discovery, MSD L15GB-1) were 
SCA1 patient iPSC-derived neuronal cells and GSK690693 treatment
Fibroblast samples were collected from a donor skin biopsy and expanded to passage three. Induced pluripotent stem cells (iPSCs) were generated by lentiviral reprogramming with the four pluripotency genes (C-MYC, KLFM3, OCT4 and SOX2).
iPSCs were differentiated for two weeks using Stem Cell Technologies Neural Induction
Protocol. Neural progenitor cells (NPCs) were expanded on PLO/L-coated plates and frozen. Differentiation of NPCs was performed for seven days using DMEM/F12, 100 ng/ml FGF8, 200 ng/mL SHH and 1:100 N2 supplement. Differentiated cells were stained for the neuronal marker Beta III Tubulin to confirm that they were restricted neural progenitor cells. For drug treatments, cells were treated for two days with 10 µM
GSK690693. Cells were lysed in Tris-Triton lysis buffer and extracted protein was processed and analyzed by western blotting. Phosphorylated ATXN1 was labeled with 1 ng/µl MoAb-17 and total ATXN1 was labeled with the anti-ATXN1 antibody 11750.
Blots were quantified on ImageQuant and normalized to GAPDH expression. dilution to detect total Atxn1 on western blots.
GSK690693 treatment in
Histology and immunostaining
Animals were anesthetized and transcardially exsanguinated with PBS and perfused using 10% formalin. Brains were post-fixed 1 hr to overnight in 10% formalin and placed in PBS before sectioning. Cerebella were sectioned into 50 um parasagittal sections using a vibratome. Epitopes were exposed using antigen retrieval by boiling sections four times 
RNA isolation and sequencing
Total RNA was isolated from dissected cerebella using TRIzol Reagent (Life Technologies, Carlsbad, California) following the manufacturer's protocols. Cerebella were homogenized using an RNase-Free Disposable Pellet Pestles in a motorized chuck.
For RNA-sequencing, RNA was further purified to remove any organic carryover using (Table S1 ). Library creation was completed using oligo-dT purification of polyadenylated RNA, which was reverse transcribed to create cDNA. cDNA was fragmented, blunt-ended, and ligated to barcoded adaptors. Library was size selected to Reads were aligned to the mouse reference genome (mm10) with Tophat2 [26] using mostly default parameters with two exceptions: mate inner distance and standard deviation were adjusted to the data and using a gene annotation model only looking for supplied junctions (mm10 gtf file from iGenomes). Reads were quantified using Cuffquant [27, 28] , and differential gene expression was determined with Cuffdiff2 using default parameters [29] . Genes/introns with a q≤0.05 were considered significant.
Genome tracks were visualized with Integrated Genomics Viewer (Broad Institute).
Results were graphed with CummeRbund [http://compbio.mit.edu/cummeRbund/ [30] ].
Pathway and clustering analysis was completed with Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, California). Normalized expression values of all genes across all samples were prepared from Cuffquant results using Cuffnorm [28] . The iGenomes mm10 gtf contains both miRNAs and snoRNAs, which are too small to be accurately sequenced using standard RNA-seq library preparation and sequencing.
Including these short transcripts in the expression data used for the PCA resulted in PCs driven by the extreme expression of a few miRNAs and snoRNAs. As a result, the expression data used in the PCA was re-quantified using Cuffquant and Cuffnorm after removing miRNAs and snoRNAs from the iGenomes gtf.
Expression analyses
Gene expression analyses were performed using the Tuxedo pipeline [26, 28] . Initial read quality was assessed using FastQC [31] and reads trimmed to remove low quality 3' ends and adapter contamination using Trimmomatic [32] . Reads were aligned to the mouse reference genome (mm10) with Tophat2 [26] using mostly default parameters with two exceptions: mate inner distance and standard deviation were adjusted to the data and using a gene annotation model only looking for supplied junctions (mm10 gtf file from iGenomes). Reads were quantified using Cuffquant [27, 28] , and differential gene expression was determined with Cuffdiff2 using default parameters [29] . Genes/introns with a q≤0.05 were considered significant. Genome tracks were visualized with Integrated Genomics Viewer (Broad Institute). Results were graphed with CummeRbund [30] . Pathway and clustering analysis was completed with Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, California). Normalized expression values of all genes across all samples were prepared from Cuffquant results using Cuffnorm [28] . The iGenomes mm10 gtf contains both miRNAs and snoRNAs, which are too small to be accurately sequenced using standard RNA-seq library preparation and sequencing.
WGCNA
FPKM abundance estimates for all 27 samples were produced by CuffNorm [29] and were log2 transformed (log2(FPKM+1)) for WGCNA analysis [33] . The WGCNA R
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Behavioral analyses
Behavioral assessments were performed at the University of Minnesota's Mouse
Behavior Core facility. Assessor was blinded to mouse genotypes. 
Statistical analysis
Data are expressed as the means ± standard error of mean (SEM). Statistical
analyses were performed using GraphPad Prism software (version 6.0c).
Significant differences were based on either t-test, one-way, or two-way analysis of variance (ANOVA) followed by Bonferroni or Dunnett post-hoc test, depending on the analysis (see Figure legends) . p<0.05 were considered as statistically significant differences.
Results
In vitro phosphorylation of ATXN1-S776 by MSK1, MSK2, and PKA
Previous evidence suggests that three kinases can phosphorylate ATXN1 at S776: MSK1, MSK2, and PKA [12, 17] . To compare the relative abilities of these kinases to phosphorylate ATXN1-S776, an in vitro kinase assay was developed that utilized mass spectroscopic analysis to quantitate the degree to which purified MSK1, MSK2, and PKA phosphorylated ATXN1 at the seven identified phosphorylation sites
[https://phosphomouse.hms.harvard.edu/]. As shown in Table 3 , only peptides containing S776 were significantly phosphorylated above background by MSK1, MSK2, and PKA.
Although MSK1 and 2 phosphorylated S776 to a slightly higher degree, the results suggest that all three enzymes can contribute to the phosphorylation of Ser776 of ATXN1. 
Phosphorylation of S776 regulates mammalian ATXN1 levels
Using an in vitro cerebellar lysate kinase assay, evidence suggested that PKA can phosphorylate ATXN1 at S776 [12] . To gain further evidence supporting a role for PKA in ATXN1-S776 phosphorylation, a modification of the in vitro mouse cerebellar extract kinase assay was used to assess a panel of six kinase inhibitors with a range of activity against PKA for their ability to affect the S776 phosphorylation status of ATXN1 Subsequently, we became aware of a small molecule GSK690693, 4-[2-(4-
as a potent inhibitor of the kinase AKT for the potential treatment of tumors in which AKT is activated [34, 35] . Analysis of GSK690693 revealed that it inhibited members of the AGC kinase family including PKA with nanomolar IC50s [34] . To confirm GSK690693 is a PKA inhibitor, a kinase inhibition profile was generated yielding the following results: IC50 for AKT1, 4.1 nM;
IC50 for PKA (PRKACA), 8.7 nM; IC50 for ROCK2, 323 nM; IC50 for MSK1, 492 nM;
and IC50 for MSK2, 1,130 nM. Next the IC50 of GSK690693 for ATXN1-S776 phosphorylation was determined. ATXN1-S776[30Q] phosphorylation was measured using MoAB-17, a mouse monoclonal that recognizes phospho-S776-ATXN1 ( Figure   S2 ). The ability of GSK690693 to inhibit S776 phosphorylation was compared to the PKA inhibitor H89 and to the compound SB-747651A, an MSK inhibitor with an IC50 of 11 nM and approximately 10-fold less inhibitory activity towards PKA [36] . Prkaca and Prkacb, respectively [37] . Prkaca is highly expressed in the cerebellum, including Purkinje cells. In contrast, Prkacb expression is much lower and not detected in Purkinje cells [38, 39] . Thus, we reasoned that targeting Prkaca expression/activity would be an effective strategy for studying the contribution of PKA signaling in SCA1 mouse cerebellum. To accomplish this, we adapted an approach developed by Shokat [40] in which the ATP-binding site gatekeeper amino acid of PKA Cα is mutated from a methionine to an alanine at residue 120 (M120A). The engineered kinase becomes a potentially analog-sensitive allele because it can be specifically targeted by an inhibitor analog that contains a bulky substituent complementing the enlarged ATP binding pocket [40, 41] . In addition, previous studies report that PKA Cα with a M120A mutation (CαM120A) results in decreased expression of CαM120A mRNA and protein [21] . Prkaca, an initial Cre recombination step was done to delete the NEO cassette (flanked by lox 1 and lox 2), generating CαLoxM120A mice ( Figure 3A) . We then crossed CαLoxM120A mice to Sox2Cre mice to obtain mice with a Prkaca M120A allele (CαM120A) expressed in all tissues ( Figure 3A ). These were bred to homozygosity (Cα M120A/M120A ) for Prkaca CαM120A to completely replace wild type Prkaca. To
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A N U S C R I P T ;Cα M120A/M120A cerebellar extracts ( Figure 3G, 3H) . Intriguingly, in the case of Atxn1[2Q]-pS776 and total
Atxn1
[2Q] no alteration in levels were detected ( Figure 3G , is Figure 4A ). The following week, 
A C C E P T E D M A N U S C R I P T
24
ATXN1 to control levels ( Figure S4B ). Other components of the PKA holoenzyme (RII, RIb) or PKA signaling in PCs (AKAP150) were also unchanged (data not shown).
The ATP-binding site analogue 1-NM-PP1 is reported to selectively inhibit genetically engineered kinases, be cell permeable, and cross the blood brain barrier in mice when delivered in drinking water or by IP injection [21, 43] . However, in our hands, all attempts to inhibit CαM120A with 1-NM-PP1 in cerebellar slices or in vivo failed. performing wt/FVB were selected for cerebellar RNA isolation (the last two groups having comparable performance). Cerebellar RNA libraries were generated and subjected to HiSeq 2500 sequencing. A total of 1,621,761,236 paired-end reads were generated, with each sample having an average of 108,117,416 reads. Reads were mapped to the UCSC mm10 mouse annotated genome using Hisat2 (Table S1 ).
Weighted Gene Coexpression Network Analysis (WGCNA) was used to identify genes that are similarly expressed in cerebella of mice that exhibit motor deficits versus those that did not [33, 45] Figure 5A ). The connectivity diagram in Figure 5B illustrates genes with the highest connectivity within the Pink-ataxia network. There are both upregulated (red) and Table S4 ).
Discussion
Results of this study further demonstrate that ATXN1-S776 phosphorylation regulates ATXN1 levels in vitro and in vivo. Importantly, inhibition of ATXN1-S776 phosphorylation decreased ATXN1 protein levels in SCA1 mouse cerebellar slice cultures as well as in SCA1 patient iPSC-derived neuronal cells. Furthermore, results
indicate that PKA Cα is a critical regulator of ATXN1-S776 phosphorylation in the cerebellum, particularly in Purkinje cells, a major site of SCA1 pathology [3] . Notably, in was no longer detectable (Figure 1) . Staurosporine is a readily cell permeable kinase inhibitor that we found in in vitro assays blocked ATXN1-S776 phosphorylation and PKA with a nanomolar IC50 (Figure S1 ), suggesting that PKA is a key kinase for ATXN1-S776 phosphorylation. The importance of PKA was further demonstrated using the small molecule kinase inhibitor GSK690693. This compound was originally developed as a high-affinity inhibitor of AKT [46] , yet in a kinase panel assay it inhibited PKA at nanomolar levels. GSK690693 inhibited ATXN1-S776 phosphorylation using cerebellar lysate as the kinase source (Figure 2A) . In this assay, GSK690693 inhibited ATXN1-S776 phosphorylation with an IC50 of 300 nM, 10-fold more potent than H89, a previously identified inhibitor of PKA [46] and SB757651, a MSK inhibitor [36] .
Importantly, we found GSK690693 effectively reduced wt and polyQ expanded Atxn1/ATXN1 when administered to cerebellar slices from Atxn1 66Q/2Q knock-in mice as
well as SCA1 patient iPSC-derived neurons (Figure 2B and 2C) . That this effect is a consequence of blocking PKA activity was supported by the positive control demonstrating sustained decrease in phosphorylation of other cerebellar proteins harboring the PKA consensus phosphorylation site RRX(S/T).
To date, there are data supporting the role of multiple kinases in regulating ATXN1-S776 phosphorylation; Akt, PKA, and Msk1/2. Using tissue culture cells and a Drosophila model of SCA1, Akt was the first kinase shown to regulate ATXN1-S776 phosphorylation and neurodegeneration [13] . However, subsequent studies in which mouse cerebellar lysates were immunodepleted for Akt or SCA1 mice were crossed with mice expressing a dominant-negative Akt, showed no effect on ATXN1-S776 phosphorylation, arguing against Akt as having a role in the cerebellum in regulating ATXN1-S776 phosphorylation [12] . More recently, a genetic screen revealed the RAS-MAPK-MSK1/2 pathway as one that modulates ATXN1 levels and toxicity [17] . This study found that a genetic reduction of Msk1/2 partially rescued motor and pathological SCA1-like phenotypes in two SCA1 mouse models.
Besides in vitro studies [12] , data implicating PKA as a regulator of cerebellar ATXN1-S776 phosphorylation included results from cerebellar slice studies using the PKA agonist forskolin [18] and a novel PKA inhibitory peptide [19] . Here, a role for PKA in regulating ATXN1-S776 phosphorylation was extended to an in vivo protein burden in PCs alters gene expression changes in whole cerebellum that in turn modulates motor dysfunction changes independent of cerebellar atrophy.
The Pink-ataxia WGCNA module brings forth novel signaling pathways associated with the initial motor disturbance not previously implicated in heritable cerebellar ataxia. The "Gq signaling" genes in our list include cholinergic receptor muscarinic 1 (Chrm1) and Fibroblast growth factor receptor 1 (Fgfr1) at the top (Table   S4) . Recent work has shown that mAChR1 may be involved in synaptic signaling in the cerebellum, where postsynaptic mAChR activation in Purkinje cells triggers the synthesis and release of endocannabinoids that act presynaptically on parallel fiber terminals to attenuate LTP [53] , suggesting a dynamic signaling role that may impact motor The IPA of genes within the Magenta-disease progression network also revealed GPCR signaling pathways as being significantly enriched in this module [44] . In addition, analysis of hub genes of the Magenta-disease progression module [33] showed that a substantial portion of the most highly connected hubs encoded signaling pathway components [33] . It was noted that Rgs8, a potent negative regulator of G-protein- cerebella. Cα M120A/M120A controls showed mild ML thinning compared to wt/FVB, but this was independent of age. Data are represented as mean ± SEM. Two-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Notice the symbol * indicates comparison between ages, and + indicates comparison to age-matched wild type.
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